KR20060133949A - 단백질 기능을 조절하기 위한 공간 배열의 용도 - Google Patents

단백질 기능을 조절하기 위한 공간 배열의 용도 Download PDF

Info

Publication number
KR20060133949A
KR20060133949A KR1020067003700A KR20067003700A KR20060133949A KR 20060133949 A KR20060133949 A KR 20060133949A KR 1020067003700 A KR1020067003700 A KR 1020067003700A KR 20067003700 A KR20067003700 A KR 20067003700A KR 20060133949 A KR20060133949 A KR 20060133949A
Authority
KR
South Korea
Prior art keywords
protein
codon usage
altered
gene
altered codon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020067003700A
Other languages
English (en)
Korean (ko)
Inventor
구앙웬 웨이
Original Assignee
휴이양테크 (유에스에이), 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20060133949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 휴이양테크 (유에스에이), 인크. filed Critical 휴이양테크 (유에스에이), 인크.
Publication of KR20060133949A publication Critical patent/KR20060133949A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020067003700A 2003-08-28 2004-08-26 단백질 기능을 조절하기 위한 공간 배열의 용도 Ceased KR20060133949A (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US49878503P 2003-08-28 2003-08-28
US49844903P 2003-08-28 2003-08-28
US49892303P 2003-08-28 2003-08-28
US60/498,785 2003-08-28
US60/498,449 2003-08-28
US60/498,923 2003-08-28
IN279MU2004 2004-03-05
IN280MU2004 2004-03-05
IN279/MUM/2004 2004-03-05
IN280/MUM/2004 2004-03-05

Publications (1)

Publication Number Publication Date
KR20060133949A true KR20060133949A (ko) 2006-12-27

Family

ID=34280101

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020067003700A Ceased KR20060133949A (ko) 2003-08-28 2004-08-26 단백질 기능을 조절하기 위한 공간 배열의 용도
KR1020067003699A Ceased KR20060130009A (ko) 2003-08-28 2004-08-26 변경된 공간 구조를 갖는 인터페론의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067003699A Ceased KR20060130009A (ko) 2003-08-28 2004-08-26 변경된 공간 구조를 갖는 인터페론의 용도

Country Status (7)

Country Link
EP (3) EP2325202B1 (enExample)
JP (4) JP2007503812A (enExample)
KR (2) KR20060133949A (enExample)
AU (2) AU2004269390A1 (enExample)
CA (2) CA2535902A1 (enExample)
PL (2) PL2325202T3 (enExample)
WO (2) WO2005021777A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1245215C (zh) 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
US8551469B2 (en) 2001-02-28 2013-10-08 Superlab Far East Limited Treatment of tumors and viral diseases with recombinant interferon alpha
WO2005021777A2 (en) * 2003-08-28 2005-03-10 Huiyangtech (Usa), Inc. Uses of spatial configuration to modulate protein function
US7585647B2 (en) 2003-08-28 2009-09-08 Guangwen Wei Nucleic acid encoding recombinant interferon
WO2006076014A2 (en) * 2004-04-30 2006-07-20 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Interferon-alpha constructs for use in the treatment of sars
EP1868636A4 (en) * 2005-03-09 2012-03-28 Guangwen Wei USE OF RECOMBINANT SUPERCOMPOSE INTERFERONS
CN102101886A (zh) * 2009-12-18 2011-06-22 四川辉阳生命工程股份有限公司 构象改变的重组干扰素晶体、其三维结构及应用
TWI718086B (zh) * 2013-01-07 2021-02-11 英屬維爾京群島商遠東超級實驗室有限公司 通過干擾素的經皮和/或經粘膜給藥治療骨癌、皮膚癌、皮下癌、粘膜癌和/或粘膜下癌的方法和組合物
CN111363726A (zh) 2018-12-26 2020-07-03 上海元宋生物技术有限公司 表达干扰素的溶瘤病毒及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US5372808A (en) 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
EP0861321B1 (en) * 1995-10-13 2006-05-31 President And Fellows Of Harvard College Phosphopantetheinyl transferases and uses thereof
US5874304A (en) * 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US20020043262A1 (en) * 2000-08-22 2002-04-18 Alan Langford Spray device
IL155741A0 (en) * 2000-11-03 2003-12-23 Pbl Biomedical Lab Interferons, uses and compositions related thereto
CN1245215C (zh) * 2001-02-28 2006-03-15 四川省生物工程研究中心 重组高效复合干扰素用作乙型肝炎表面抗原和e抗原抑制剂
WO2005021777A2 (en) * 2003-08-28 2005-03-10 Huiyangtech (Usa), Inc. Uses of spatial configuration to modulate protein function

Also Published As

Publication number Publication date
EP2325202B1 (en) 2014-10-22
JP5709800B2 (ja) 2015-04-30
WO2005021777A2 (en) 2005-03-10
PL2325202T3 (pl) 2015-03-31
JP2007503812A (ja) 2007-03-01
KR20060130009A (ko) 2006-12-18
AU2004279350B2 (en) 2011-03-10
EP1670817A2 (en) 2006-06-21
EP1663110A2 (en) 2006-06-07
CA2535982A1 (en) 2005-04-21
HK1091756A1 (en) 2007-01-26
AU2004269390A1 (en) 2005-03-10
HK1158231A1 (en) 2012-09-14
CA2535982C (en) 2016-11-29
PL1663110T3 (pl) 2014-07-31
JP2011083292A (ja) 2011-04-28
EP1663110B1 (en) 2013-12-18
WO2005034853A3 (en) 2006-04-27
WO2005034853A2 (en) 2005-04-21
EP1670817A4 (en) 2008-07-16
CA2535902A1 (en) 2005-03-10
WO2005021777A3 (en) 2005-05-12
EP2325202A1 (en) 2011-05-25
JP2012162567A (ja) 2012-08-30
JP5663768B2 (ja) 2015-02-04
AU2004279350A1 (en) 2005-04-21
JP2007516214A (ja) 2007-06-21
EP1663110A4 (en) 2008-07-16

Similar Documents

Publication Publication Date Title
AU2017267665C1 (en) Modulatory polynucleotides
AU2018284960B2 (en) AADC polynucleotides for the treatment of Parkinson's disease
DE69531387T2 (de) Von Adenovirus abgeleitete rekombinante Vektoren, für Gentherapie
DE69034078T2 (de) Expression von exogenen Polynukleotidsequenzen in Wirbeltieren
ES2685611T3 (es) Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
AU585579B2 (en) Recombinant alveolar surfactant protein
JP2011083292A (ja) 空間構造によるタンパク質の機能の調節
HK1000891B (en) Synthetic peptide analogs of lung surfactant protein sp-c
HK1000891A1 (en) Synthetic peptide analogs of lung surfactant protein sp-c
US20070293660A1 (en) Method for purifying granulocyte-colony stimulating factor
CN120173090B (zh) 猫血清白蛋白突变体、及其cho细胞表达方法和应用
Vasquez et al. Replication-Deficient Adenovirus Vector Transfer ofgfpReporter Gene into Supraoptic Nucleus and Subfornical Organ Neurons
CN113788891B (zh) 一种重组i型人源化胶原蛋白c1l4t及其制备方法和用途
EP0446931A1 (en) Human ciliary neuronotrophic factor, DNA sequence encoding the factor, and production of the factor by recombinant technology
WO2022188444A1 (zh) 一种新型抗代谢紊乱的fgf类似物及其应用
EP4424696A1 (en) Cyclic dinucleotide metal compound, and preparation method therefor and use thereof
US20110070195A1 (en) Uses of spatial configuration to modulate protein function
CN1910195A (zh) 通过空间构象调节蛋白质功能
CN111909246B (zh) 高效感染支持细胞的aav突变体
CN107325188A (zh) 猪血清蛋白融合猪圆环病毒Cap2蛋白的CHO细胞株的构建方法及其应用
JP2001512325A (ja) 改変型レチノブラストーマ腫瘍抑制タンパク質
EP3967706A1 (en) Aav mutant that efficiently infects supporting cells
CN120209082B (zh) 一种靶向阻断trim25与brd7蛋白结合的多肽及其应用
PT2325202E (pt) Utilizações de interferões com estrutura espacial alterada
JPH09510358A (ja) 脳−誘導神経栄養因子（ｂｄｎｆ）をコードする組み換えアデノウィルス

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20060223

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090717

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110516

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20120113

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110516

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I